Approximately 2 weeks later, when the bilateral tumors were barely measurable, 15 mice with palpable bilateral tumors, all <5 mm3, were randomized at a 1:2 ratio, with 5 mice receiving RT alone only to the R flank tumor, while the remaining 10 mice received RT and IT-CpG and IT-IC only to the R flank tumor, together with systemic administration of anti-CTLA-4. Here, CTLA4 is linked to neoplasm.